vs

Side-by-side financial comparison of Princeton Bancorp, Inc. (BPRN) and AVITA Medical, Inc. (RCEL). Click either name above to swap in a different company.

Princeton Bancorp, Inc. is the larger business by last-quarter revenue ($20.7M vs $17.6M, roughly 1.2× AVITA Medical, Inc.). Princeton Bancorp, Inc. runs the higher net margin — 29.3% vs -66.0%, a 95.3% gap on every dollar of revenue. On growth, Princeton Bancorp, Inc. posted the faster year-over-year revenue change (3.6% vs -4.3%). Princeton Bancorp, Inc. produced more free cash flow last quarter ($20.6M vs $-6.1M). Over the past eight quarters, AVITA Medical, Inc.'s revenue compounded faster (26.0% CAGR vs 9.1%).

Princeton Bancorp, Inc. is a U.S.-based bank holding company operating through its community banking subsidiary. It offers retail and commercial banking products including deposit accounts, small business loans, consumer loans, mortgages and wealth management services, primarily serving clients across New Jersey and the U.S. mid-Atlantic region.

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...

BPRN vs RCEL — Head-to-Head

Bigger by revenue
BPRN
BPRN
1.2× larger
BPRN
$20.7M
$17.6M
RCEL
Growing faster (revenue YoY)
BPRN
BPRN
+7.9% gap
BPRN
3.6%
-4.3%
RCEL
Higher net margin
BPRN
BPRN
95.3% more per $
BPRN
29.3%
-66.0%
RCEL
More free cash flow
BPRN
BPRN
$26.7M more FCF
BPRN
$20.6M
$-6.1M
RCEL
Faster 2-yr revenue CAGR
RCEL
RCEL
Annualised
RCEL
26.0%
9.1%
BPRN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BPRN
BPRN
RCEL
RCEL
Revenue
$20.7M
$17.6M
Net Profit
$6.1M
$-11.6M
Gross Margin
81.2%
Operating Margin
38.2%
-59.1%
Net Margin
29.3%
-66.0%
Revenue YoY
3.6%
-4.3%
Net Profit YoY
16.3%
-0.3%
EPS (diluted)
$0.89
$-0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BPRN
BPRN
RCEL
RCEL
Q4 25
$20.7M
$17.6M
Q3 25
$21.5M
$17.1M
Q2 25
$21.1M
$18.4M
Q1 25
$20.9M
$18.5M
Q4 24
$20.0M
$18.4M
Q3 24
$19.2M
$19.5M
Q2 24
$18.1M
$15.2M
Q1 24
$17.4M
$11.1M
Net Profit
BPRN
BPRN
RCEL
RCEL
Q4 25
$6.1M
$-11.6M
Q3 25
$6.5M
$-13.2M
Q2 25
$688.0K
$-9.9M
Q1 25
$5.4M
$-13.9M
Q4 24
$5.2M
$-11.6M
Q3 24
$-4.5M
$-16.2M
Q2 24
$5.1M
$-15.4M
Q1 24
$4.3M
$-18.7M
Gross Margin
BPRN
BPRN
RCEL
RCEL
Q4 25
81.2%
Q3 25
81.3%
Q2 25
81.2%
Q1 25
84.7%
Q4 24
87.6%
Q3 24
83.7%
Q2 24
86.1%
Q1 24
86.4%
Operating Margin
BPRN
BPRN
RCEL
RCEL
Q4 25
38.2%
-59.1%
Q3 25
38.5%
-53.6%
Q2 25
2.8%
-60.5%
Q1 25
32.9%
-63.9%
Q4 24
34.0%
-54.1%
Q3 24
-29.1%
-70.6%
Q2 24
34.1%
-102.8%
Q1 24
31.0%
-155.0%
Net Margin
BPRN
BPRN
RCEL
RCEL
Q4 25
29.3%
-66.0%
Q3 25
30.0%
-77.3%
Q2 25
3.3%
-53.9%
Q1 25
25.7%
-74.9%
Q4 24
26.1%
-63.0%
Q3 24
-23.3%
-82.9%
Q2 24
28.4%
-101.3%
Q1 24
24.9%
-168.0%
EPS (diluted)
BPRN
BPRN
RCEL
RCEL
Q4 25
$0.89
$-0.37
Q3 25
$0.95
$-0.46
Q2 25
$0.10
$-0.38
Q1 25
$0.77
$-0.53
Q4 24
$0.75
$-0.44
Q3 24
$-0.68
$-0.62
Q2 24
$0.80
$-0.60
Q1 24
$0.68
$-0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BPRN
BPRN
RCEL
RCEL
Cash + ST InvestmentsLiquidity on hand
$18.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$270.7M
$-16.6M
Total Assets
$2.3B
$56.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BPRN
BPRN
RCEL
RCEL
Q4 25
$18.2M
Q3 25
$23.3M
Q2 25
$15.7M
Q1 25
$25.8M
Q4 24
$35.9M
Q3 24
$44.4M
Q2 24
$54.1M
Q1 24
$68.2M
Total Debt
BPRN
BPRN
RCEL
RCEL
Q4 25
Q3 25
$0
Q2 25
$10.0M
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BPRN
BPRN
RCEL
RCEL
Q4 25
$270.7M
$-16.6M
Q3 25
$266.6M
$-6.7M
Q2 25
$261.9M
$-12.9M
Q1 25
$267.0M
$-4.6M
Q4 24
$262.0M
$4.5M
Q3 24
$261.5M
$12.2M
Q2 24
$244.8M
$23.9M
Q1 24
$241.8M
$32.6M
Total Assets
BPRN
BPRN
RCEL
RCEL
Q4 25
$2.3B
$56.4M
Q3 25
$2.2B
$63.7M
Q2 25
$2.2B
$58.1M
Q1 25
$2.3B
$69.6M
Q4 24
$2.3B
$79.7M
Q3 24
$2.4B
$81.1M
Q2 24
$2.0B
$87.8M
Q1 24
$2.0B
$97.4M
Debt / Equity
BPRN
BPRN
RCEL
RCEL
Q4 25
Q3 25
0.00×
Q2 25
0.04×
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BPRN
BPRN
RCEL
RCEL
Operating Cash FlowLast quarter
$21.5M
$-5.4M
Free Cash FlowOCF − Capex
$20.6M
$-6.1M
FCF MarginFCF / Revenue
99.3%
-34.7%
Capex IntensityCapex / Revenue
4.3%
3.8%
Cash ConversionOCF / Net Profit
3.54×
TTM Free Cash FlowTrailing 4 quarters
$29.2M
$-33.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BPRN
BPRN
RCEL
RCEL
Q4 25
$21.5M
$-5.4M
Q3 25
$4.9M
$-5.2M
Q2 25
$3.1M
$-10.2M
Q1 25
$1.3M
$-10.3M
Q4 24
$14.7M
$-8.1M
Q3 24
$1.2M
$-7.2M
Q2 24
$4.3M
$-12.8M
Q1 24
$4.8M
$-20.9M
Free Cash Flow
BPRN
BPRN
RCEL
RCEL
Q4 25
$20.6M
$-6.1M
Q3 25
$4.7M
$-6.2M
Q2 25
$2.9M
$-10.8M
Q1 25
$1.1M
$-10.5M
Q4 24
$13.2M
$-9.7M
Q3 24
$766.0K
$-11.0M
Q2 24
$3.9M
$-15.4M
Q1 24
$4.8M
$-22.0M
FCF Margin
BPRN
BPRN
RCEL
RCEL
Q4 25
99.3%
-34.7%
Q3 25
21.6%
-36.1%
Q2 25
13.7%
-58.4%
Q1 25
5.0%
-56.9%
Q4 24
65.9%
-52.7%
Q3 24
4.0%
-56.1%
Q2 24
21.8%
-101.6%
Q1 24
27.3%
-198.2%
Capex Intensity
BPRN
BPRN
RCEL
RCEL
Q4 25
4.3%
3.8%
Q3 25
1.1%
5.5%
Q2 25
1.2%
2.8%
Q1 25
1.0%
1.2%
Q4 24
7.6%
8.8%
Q3 24
2.2%
19.2%
Q2 24
2.1%
17.5%
Q1 24
0.4%
10.3%
Cash Conversion
BPRN
BPRN
RCEL
RCEL
Q4 25
3.54×
Q3 25
0.76×
Q2 25
4.57×
Q1 25
0.23×
Q4 24
2.82×
Q3 24
Q2 24
0.84×
Q1 24
1.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons